The current state of multidrug-resistant gram-negative bacilli in North America (Q37069191)

18 August 2017

1 reference

title

The current state of multidrug-resistant gram-negative bacilli in North America (English)

1 reference

18 August 2017

main subject

Gram-negative bacteria

0 references

multiple drug resistance

1 reference

2

Joseph L Kuti

1 reference

18 August 2017

3

David P Nicolau

1 reference

18 August 2017

Anthony M Nicasio

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

28

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

235-249

1 reference

STAPHYLOPENICILLINASE--ITS ROLE IN PENICILLIN RESISTANCE. II. AN ALTERNATE METHOD OF PENICILLIN RESISTANCE IN VIVO BY STAPHYLOCOCCUS AUREUS.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

NEW EPIDEMIC STRAIN OF STAPHYLOCOCCUS AUREUS. EMERGENCE AND SPREAD IN A GENERAL HOSPITAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Overview of nosocomial infections caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

The structure of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

What's new in antibiotic resistance? Focus on beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Aminoglycoside antibiotic resistance by enzymatic deactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Mechanisms of antimicrobial resistance in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Nosocomial outbreak due to extended-spectrum-beta-lactamase- producing Enterobacter cloacae in a cardiothoracic intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Extended-spectrum beta-lactamases: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Expanded-spectrum beta-lactamase-producing strains of E. coli: origin, characteristics and incidence in Southern Alicante (Spain) in the period 1999-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Resistance patterns among nosocomial pathogens: trends over the past few years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Of Pseudomonas, porins, pumps and carbapenems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Emerging carbapenemases in Gram-negative aerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (199

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Extended spectrum beta-lactamase-producing Klebsiella pneumoniae chronic ambulatory peritoneal dialysis peritonitis treated successfully with polymyxin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Colistin for Klebsiella pneumoniae-associated sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Tigecycline: clinical evidence and formulary positioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Rapid development of Acinetobacter baumannii resistance to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Pharmacodynamics of antimicrobials: treatment optimisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.2.235

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.2.235

1 reference

18 August 2017

1 reference